Objective The risk characteristics of epirubicin-induced cardiotoxicity in patients with malignant tumors were analyzed and an early prediction model was established.Methods From may 2023 to may 2024,320 patients with ma-lignant tumors in the Affiliated Cancer Hospital of Xinjiang Medical University were selected for analysis.All patients were treated with epirubicin chemotherapy.They were divided into cardiac injury group and control group according to whether heart injury occurred.General data,electrocardiogram and other items were compared between the two groups.Multivariate Logistic regression was used to analyze the relationship between relevant indicators and the risk of epirubicin-induced car-diotoxicity in patients with malignant tumors,and R software was used to establish and verify the nomogram prediction model of each factor to predict the risk of epirubicin-induced cardiotoxicity in patients with malignant tumors.Results Of the 320 patients,18 lost contact;Sixty-two cases(20.53％)were classified as heart injury group,among which T wave or ST segment changes were the highest,followed by EF changes.The remaining 240 patients were the control group.The age,the proportion of patients with hypertension,the accumulation of epirubicin,The Times of chemotherapy and the proportion of patients with radiotherapy in the heart injury group were higher than those in the control group(t/x2/P=6.001/＜0.001,6.580/0.010,7.631/＜0.001,7.117/＜0.001,6.380/0.012).Multivariate Logistic regression analysis showed that higher age,hy-pertension,the accumulation of epirubicin,the number of chemotherapy,and combined radiotherapy were independent risk factors for the risk of epirubicin induced cardiotoxicity in patients with malignant tumors[OR(95％CI)=1.088(1.037-1.142)、2.473(1.084-5.642)、1.676(1.373-2.046)、1.012(1.007-1.016)、2.154(1.021-4.545)].The factors influencing the risk of epirubicin-induced cardiotoxicity in patients with malignant tumors were included in the column diagram,and the C-index of the factors predicting the risk of epirubicin-induced cardiotoxicity in patients with malignant tumors was 0.912.Conclusion The column graph constructed by the accumulation of epirubicin and the number of chemotherapy plays a certain role in predicting the risk of epirubicin-induced cardiotoxicity in malignant tumor patients,which helps to adjust the treatment regimen early and prevent the occurrence of cardiotoxicity.
Malignant tumorEpirubicinCardio toxicityPrediction model
万方数据
维普
